Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time. Read More ›

Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations. Read More ›

Patients with KRAS G12C non–small-cell lung cancer appear to have improved progression-free survival before immunotherapy than patients with non-KRAS G12C lung cancer, but there was no improvement in overall survival between the 2 groups. Read More ›

More severe interstitial lung disease with more severe radiological features was found on second occurrence in patients with lung cancer who were rechallenged with ICI treatment. Read More ›

Liquid biopsy improves turnaround time for molecular genotyping, but further improvement in next-generation sequencing is recommended. Read More ›

A recent study identified several risk factors associated with the development of nephrotoxicity when using pemetrexed in patients with non–small-cell lung cancer. Read More ›

Researchers identified an association between nutritional status, treatment protocols, and survival in patients with advanced non–small-cell lung cancer. Read More ›

Recently released study findings on PD-1/PD-L1 immunotherapy in young and elderly patients with metastatic NSCLC found the treatment is safe and effective in both patient cohorts. Read More ›

Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost. Read More ›

A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status. Read More ›

Page 1 of 20

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: